The Weekly Roundup: September 29-October 3

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Psoriatic Arthritis

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

Top 5 Articles of the Month: September 2025

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Dermatology Times September 2025 Print Recap

Learn more about the in-depth topics covered in the September 2025 print issue of Dermatology Times.

Q&A: Jon Friis on How Generative AI Could Transform Dermatology Workflows

Miiskin integrates generative AI into dermatology, enhancing efficiency and patient access while reducing clinician workload and administrative tasks.

How Ruxolitinib’s Expanded Indication Will Impact Pediatric Patients With AD

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Efficacy Gaps Remain Despite Therapeutic Advances in HS

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Interview Intersection: Expert Interviews From September 2025

Dermatology Times is recapping our exclusive expert interviews from the month of September.

Excimer Laser Plus Tacrolimus Shows Superior Psoriasis Results

Both treatments were well tolerated, with only mild, self-limiting adverse effects reported.

Dermatology Times' Monthly Crossword: September 2025

Test your knowledge of key words and terms associated with dermatology news from the last month.

Derm Dispatch: Interpreting Clinical Trial Data Beyond the Abstract

Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.

Dermatology Times September 2025 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of September.

FDA Approves Remibrutinib, First Oral BTK Inhibitor for CSU

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Derm Dispatch: Interpreting Clinical Trial Data Beyond the Abstract

Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.

MoonLake Shares Findings from Dual Phase 3 Trials of Sonelokimab

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Dermatology Conferences and Meetings Calendar: October 2025

Dermatology Times has compiled a list of dermatological meetings taking place during the month of October.

New Hope for Chronic Hives on World Urticaria Day 2025

World Urticaria Day raises awareness about chronic spontaneous and inducible urticaria, highlighting treatment advancements and patient challenges.

Q&A: Danielle Jonas on Eczema Awareness Month, Finding Clinician Support, and Why Laundry Impacts Skin Health

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

Lisa Espinoza, MD, Discusses Key Findings from Allergan Aesthetics’ Report on HA Fillers

Lisa Espinoza, MD, discusses key insights from Allergan's Hyaluronic Acid Injectable Fillers Report, highlighting patient satisfaction and evolving aesthetic trends.

ORKA-001 and the Everlast Trial: Exploring the Next Step in IL-23 Inhibition

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

From Clinic to Conferences: How Heather Gates, PA-C, Blends Patient Care, Education, and Entrepreneurship in Her New Role

Heather Gates, PA-C, brings her dermatology expertise into a conference management business to enhance education for professionals of all levels.

FDA Recommends Against Immediate BLA Filing for Melanoma Vaccine Candidate

The vaccine is designed to stimulate T cell responses against IDO1- and PD-L1–positive cells within the tumor microenvironment.

Establishing Trust and Innovation in Dermatology Clinical Trials

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin is improving trial adherence through bilingual staff, modernizing operations with digital tools, and strengthening community.

Priority Review Requested for Rare Disease Therapy Bitopertin

Disc Medicine filed an NDA for bitopertin to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in patients ≥12 years.

Why Patient Education Is the Foundation of Natural Yet Noticeable Aesthetic Results

Lisa Espinoza, MD, highlights the importance of patient education and tailored HA filler treatments for achieving natural cosmetic results.

Phase 2 Trial Highlights Efficacy of Novel Urticaria Therapy

Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.

Dupilumab and BTK Inhibitors Expand Options in CSU

Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.

WHO Adds Psoriasis Biologics, AD Moisturizers, and Sunscreen for Albinism to Essential Medicines List

WHO includes adalimumab and ustekinumab for psoriasis, plus sunscreen for albinism, enhancing global skin health and access to essential treatments.

Brian Kim, MD, FAAD, on the Impact of the Cell Symposia: Neuro-immune Axis Meeting

Brian Kim, MD, FAAD, explores the Cell Symposia: Neuro-immune Axis, highlighting neuroimmunology's impact on dermatology and systemic medicine.

LEO Pharma Finalizes Acquisition of Spesolimab for GPP

Spesolimab joins LEO Pharma’s dermatology portfolio to further expand spesolimab’s reach for patients worldwide with generalized pustular psoriasis.